-
Continue reading →: Lee Pharma’s Compulsory License Application Rejected
A Compulsory License (CL) application was filed by Lee Pharma with respect to AstraZeneca’s patent covering the anti-diabetes drug Saxagliptin. The Controller General of Patents issued a notice stating the Applicant’s failure to establish a prima facie case. The Controller General after hearing the Applicant on establishment of a prima facie…
-
Continue reading →: The battle continues…
For those of us who thought that Roche vs CIPLA dispute concerning Erlotinib Hydrochloride was over following from the findings by the Division Bench, here is an update – CIPLA has now filed a SLP before the Supreme Court of India. Stay tuned for more updates on this segment.
-
Continue reading →: Merck’s Divisional Application Refused by Delhi, Patent Office
Merck’s divisional patent application 4700/DELNP/2009 has been refused by the Delhi patent office vide an order dated 13th January 2016. The parent application claims are related to an antibiotic compound and method of making the claimed antibiotic, while the divisional application as submitted by the agent of the Applicant was…
-
Continue reading →: F. Hoffmann La Roche vs CIPLA- A Digest
The long pending patent dispute ensuing between CIPLA and F. Hoffmann La Roche over Roche’s lung cancer drug Erlotinib hydrochloride (sold under the name of Tarceva) has been resolved after the Division bench of the Delhi High Court pronounced in its judgement that CIPLA infringes Roche’s patent. This judgement has contributed…
-
Continue reading →: New Numbering System
CGPDTM has launched a new unique numbering system for Patent Applications and Requests for Examination filed at the Patent Office w.e.f. 1st January, 2016. The numbering system has been standardized and streamlined with a view to attain uniformity in accessing and processing applications by all Patent offices in India (Delhi,…
-
Continue reading →: GOI to bring out a new national policy for IPR
The government of India is in the process of amending the patent rules so as to speed up patent filing and approval, in particular to promote “Make in India” and “startup India”. The government had created a think tank to provide recommendations and draft the IPR Policy. The new IPR…
-
Continue reading →: The Draft patent (Amendment) Rules, 2015
The Draft patent (Amendment) Rules, 2015 is a progressive initiative by the Government in compliance with the orders of the Hon’ble Delhi High Court in the Nitto Denko case to reduce backlog and provide a fee structure for sequence listing in biotech cases. While the attempt is appreciated, the New…
-
Continue reading →: AD-INTERIM RELIEF TO SERGI: ALLOWED TO MANUFACTURE AND DEAL IN TRANSFORMERS
In the patent battle raging between Sergi India and CTR in the Bombay High Court, a Division Bench order provides some respite for the former and allowed Sergi to continue manufacture and deal in transformers. Sergi had appealed the injunction reinstated against it by a Single Judge bench on the 23rd day…
-
Continue reading →: SWEET VICTORY FOR ROCHE -VALIDITY OF PATENT UPHELD; INFRINGEMENT OF PATENT ESTABLISHED
In another landmark judgement by the Delhi High Court towards expounding and interpreting the Patent law in India in F-Hoffman La Roche vs CIPLA_2015, the Court not only upheld the validity of the suit patent but also ascertained that the patent is being infringed. The suit patent (IN196774) was granted…
Greetings
Welcome to Patents Rewind, Anand and Anand’s Patents and Designs blog that offers you an Indian perspective on issues surrounding patent and design eligibility and enforcement through latest case law and developments in the Indian patents and designs landscape.
Let’s connect
Join us!
Stay updated with our posts.
